KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $603,360 | -17.0% | 18,926 | +4.6% | 0.00% | – |
| Q2 2023 | $727,097 | +78.4% | 18,096 | +89.5% | 0.00% | – |
| Q1 2023 | $407,658 | +5.0% | 9,547 | +18.1% | 0.00% | – |
| Q4 2022 | $388,144 | +35.2% | 8,083 | +5.8% | 0.00% | – |
| Q3 2022 | $287,000 | +51.1% | 7,641 | +10.9% | 0.00% | – |
| Q2 2022 | $190,000 | -49.1% | 6,889 | +0.5% | 0.00% | – |
| Q1 2022 | $373,000 | +3.6% | 6,854 | +11.4% | 0.00% | – |
| Q4 2021 | $360,000 | +48.1% | 6,150 | +0.1% | 0.00% | – |
| Q3 2021 | $243,000 | +57.8% | 6,144 | +69.5% | 0.00% | – |
| Q2 2021 | $154,000 | -27.0% | 3,625 | +6.1% | 0.00% | – |
| Q1 2021 | $211,000 | -13.9% | 3,416 | -1.8% | 0.00% | – |
| Q4 2020 | $245,000 | +665.6% | 3,480 | +315.3% | 0.00% | – |
| Q3 2020 | $32,000 | -23.8% | 838 | -25.7% | 0.00% | – |
| Q2 2020 | $42,000 | – | 1,128 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |